Gilead Sciences' Cancer Folly

http://www.fool.com/investing/general/2016/03/23/gilead-sciences-cancer-folly.aspx


(NASDAQ:GILD) reported last week that it has halted six trials that were evaluating the use of its oncology drug, Zydelig, in newly diagnosed cancer patients. The news came alongside an FDA warning to doctors of unexpected deaths within those trials, and it's a big blow to Gilead Sciences' plans to become a major player in the indication.